335293-23-7

Upstream product

• 51719-67-6 3,4,5-trimethylphenylacetic acid 

Downstream Products

• 671232-88-5 7-chloro-4-hydroxy-6-iodo-3-(3,4,5-trimethylphenyl)-1H-quinolin-2-one 
• 362604-16-8 dimethyl 6-N-(3,4,5-trimethylphenyl)acetylamino-4-chloro-1,3-isophthalate 
• 335293-20-4 4-(2-(N-tert-butoxycarbonylazetidin-2(S)-yl)ethoxy)-7-chloro-2-oxo-3-(3,4,5-trimethylphenyl)-1,2-dihydroquinoline-6-carboxylic acid pyrimidin-4-ylamide 
• 335293-24-8 4-(2-(N-tert-butoxycarbonylazetidin-2(S)-yl)ethoxy)-7-chloro-2-oxo-3-(3,4,5-trimethylphenyl)-1,2-dihydoquinoline-6-carboxylic acid 
• 335293-17-9 6-carbomethoxy-7-chloro-4-hydroxy-3-(3,4,5-trimethylphenyl)-1H-quinolin-2-one 
• 671232-87-4 methyl 4-chloro-5-iodo-2-N-(3,4,5-trimethylphenyl)acetylaminobenzoate 

Relevant academic research and scientific papers

A potent, nonpeptidyl 1H-quinolone antagonist for the gonadotropin-releasing hormone receptor

Extensive development of the structure - activity relationships of a screening lead determined three important pharmacophores for gonadotropin-releasing hormone (GnRH) receptor antagonist activity. Incorporation of the 3,4,5-trimethylphenyl group at the 3

Quinolones as gonadotropin releasing hormone (GnRH) antagonists: Simultaneous optimization of the C(3)-aryl and C(6)-substituents

A series of 3-arylquinolones was prepared and evaluated for their ability to act as gonadotropin releasing hormone (GnRH) antagonists. A variety of substitution patterns of the 3-aryl substituent are described. The 3,4,5-trimethylphenyl substituent (23h) was found to be optimal. (C) 2000 Elsevier Science Ltd. All rights reserved.